Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

This Special Issue examines state-of-the-art in-cell NMR spectroscopy as it relates to biological systems of increasing complexity. The compendia of research and recent innovations from prominent laboratories in the field of solid state and solution in-cell NMR spectroscopy, metabolomics and technology development are presented. The work establishes in-cell NMR spectroscopy as the premier method for determining the structures and interaction capabilities of biological molecules at high resolution within the delicately intricate interior of living cells, and the means of utilizing cells as living laboratories to directly assess the effects of exogenous and endogenous stimuli on cell physiology.]

protein NMR --- time-resolved NMR --- Ribosome --- structural calculation 4 --- crystalline and amorphous starch --- in-cell NMR --- protein dynamics --- DNP --- protein modification --- Tau --- spectrum reconstruction 3 --- mRNA --- Thioredoxin --- protein structure --- protein interactions --- drug discovery --- protein structure determination 1 --- review --- enzyme activity --- MARK2 phosphorylation --- post-translational modifications --- Dihydrofolate reductase --- mammalian cells --- target engagement --- non-uniform sampling 2 --- paramagnetic effects --- protein structure-function --- cross-correlated relaxation --- structure function --- rRNA --- 2D INADEQUATE --- lipid membrane --- Thymidylate synthase --- whole cell NMR --- enzyme kinetics --- magic-angle spinning --- live cell --- solid-state NMR --- Adenylate kinase --- DNA --- in-situ NMR --- antimicrobial peptide --- NMR spectroscopy --- intrinsically disordered proteins

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

The Special Issue "Anticancer Drugs 2021" of Pharmaceuticals is focused on recent significant advances in the design, synthesis, molecular mechanism of action and therapeutic applications of anticancer drugs. This collection of preclinical research papers and reviews includes designed chemotherapeutic agents, targeted therapies and biological agents. The rationalization for the biological activity of these drugs is presented, which helps to guide the design of more effective agents. Structure–activity relationships, together with the biological context in which targets are selected for oncology drug development, are also considered.

thymidylate synthase --- cytotoxicity --- 1,2,3-triazole --- 1,3,4-oxadiazole --- 5-fluoruracil --- pemetrexed --- docking --- 3,4′-bis-guanidino --- 3-amino-4′-guanidino --- diphenyl ether --- phenyl pyridyl ether --- intramolecular hydrogen bond --- cancer cell viability --- HL-60 --- BRAF --- apoptosis --- thieno[2,3-d][1,2,3]triazine --- acetamide --- H1299 --- HER2 --- EGFR --- Bcl-2 inhibitors --- Indole-based analogues --- benzimidazole --- MTT cytotoxic assay --- cell cycle analysis --- DNA fragmentation --- ELISA --- solid/lipid nanoparticles --- phenstatin --- letrozole --- tubulin polymerisation inhibitor --- aromatase inhibitor --- breast cancer --- hybrid molecule --- dual-targeting molecule --- designed multiple ligand --- NaMSA --- cyclophosphamide --- histopathology --- testis --- urinary bladder --- anticancer agents --- enantioselective synthesis --- gastric adenocarcinoma --- tryptophanol --- concentration-guided dosing --- model informed dosing --- physiologically based pharmacokinetics --- sorafenib --- tyrosil-DNA-phosphodiesterase 1 --- adamantane --- resin acid --- TDP1 --- cytotoxic agents --- apoptosis induction --- HT-29 cells --- MDA-MB-231 cells --- mechanism prediction --- STAT inhibitors --- miR-21 --- hydrazide derivatives --- nitrogen scaffolds --- mitoxantrone --- cardiotoxicity --- inflammation --- oxidative stress --- age --- cumulative dose --- Trk --- NTRK --- tissue-agnostic --- larotrectinib --- entrectinib --- Trk fusion --- protein kinase inhibitors --- USFDA --- cancer --- patent review --- generic product --- doxazosin --- MD simulations --- combretastatin A-4 --- cytotoxic activity --- hybrid compounds --- indazole --- mucin --- MUC1 --- MUC16 --- immunotherapy --- cancer vaccine --- CAR (chimeric antigen receptor) --- ADC (antibody-drug conjugate) --- thiourea --- interleukin-6 --- trypan blue assay --- chalcones --- exportin-1 --- covalent binding --- CovDock --- anticancer activity --- xanthone --- in vitro --- in vivo --- isolation --- synthesis --- heterocyclic compound --- benzenesulfonamides --- imidazoles --- alkylated --- colony formation --- tumor spheroids --- HDAC inhibitors --- chalcone --- dual inhibitors --- carvedilol --- kidney --- toxicity --- 7-deaza-4′-thioadenosine derivatives --- multi-kinase inhibitor --- anticancer --- nucleoside --- Imiquimod --- drug efflux --- multidrug resistance --- Toll-Like Receptor --- n/a --- 3,4'-bis-guanidino --- 3-amino-4'-guanidino --- 7-deaza-4'-thioadenosine derivatives